Open Access

Protective effects of fisetin against myocardial ischemia/reperfusion injury

  • Authors:
    • Lihui Long
    • Xuliang Han
    • Xingming Ma
    • Kai Li
    • Linjie Liu
    • Juanni Dong
    • Bei Qin
    • Kelin Zhang
    • Kuan Yang
    • Honglin Yan
  • View Affiliations

  • Published online on: March 6, 2020     https://doi.org/10.3892/etm.2020.8576
  • Pages: 3177-3188
  • Copyright: © Long et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The underlying mechanism of the myocardial protective effect of fisetin was studied in a rat ischemia/reperfusion injury model. Sprague‑Dawley rats were randomly assigned to seven groups and pretreated with different solutions by gavage administration. A rat model of cardiac ischemia/reperfusion injury was established. Plasma levels of Von Willebrand factor (vWF) were determined by ELISA, flow cytometry was used to determine the level of cardiomyocyte apoptosis and 2,3,5‑triphenyltetrazolium staining was used to determine the size of myocardial infarcts. Hematoxylin and eosin‑stained sections of myocardial tissues were examined for pathological changes. Expressions of nuclear factor (NF)‑κB and matrix metallopeptidase 9 (MMP‑9) were measured by immunohistochemistry. Compared with the model group, rats pretreated with fisetin, quercetin and aspirin showed significant prolongation of clotting time, prothrombin time, thrombin time and activated partial thromboplastin time. Fisetin treatment better maintained the integrity of myocardial fibers and nuclear integrity, reduced the percentage of apoptotic myocardial cells, inhibited expression of NF‑κB, decreased the loss of MMP‑9 and reduced nuclear translocation of NF‑kB. Rats pretreated with fisetin also demonstrated a significant decrease in plasma levels of vWF. In addition, the protective effect of fisetin on myocardial cells was found to be dose dependent.
View Figures
View References

Related Articles

Journal Cover

May-2020
Volume 19 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Long L, Han X, Ma X, Li K, Liu L, Dong J, Qin B, Zhang K, Yang K, Yan H, Yan H, et al: Protective effects of fisetin against myocardial ischemia/reperfusion injury. Exp Ther Med 19: 3177-3188, 2020
APA
Long, L., Han, X., Ma, X., Li, K., Liu, L., Dong, J. ... Yan, H. (2020). Protective effects of fisetin against myocardial ischemia/reperfusion injury. Experimental and Therapeutic Medicine, 19, 3177-3188. https://doi.org/10.3892/etm.2020.8576
MLA
Long, L., Han, X., Ma, X., Li, K., Liu, L., Dong, J., Qin, B., Zhang, K., Yang, K., Yan, H."Protective effects of fisetin against myocardial ischemia/reperfusion injury". Experimental and Therapeutic Medicine 19.5 (2020): 3177-3188.
Chicago
Long, L., Han, X., Ma, X., Li, K., Liu, L., Dong, J., Qin, B., Zhang, K., Yang, K., Yan, H."Protective effects of fisetin against myocardial ischemia/reperfusion injury". Experimental and Therapeutic Medicine 19, no. 5 (2020): 3177-3188. https://doi.org/10.3892/etm.2020.8576